The advent of tau tracers, which include the first generation tracer [18F]flortaucipir (FTP), as well as second generation tracers ([18F]MK6240, [18F]RO-948), [18F]PI2620, [18F]JNJ-311, [18F]GTP1) has enabled characterisation of tau regional distribution in vivo [1, 2]: FTP signal correlates with tau pathology at post-mortem [3, 4], distinguishes AD from healthy controls and other neurodegenerative conditions [5–7] and is associated with cognitive impairment, cortical hypometabolism, neurodegeneration and future disease progression [5, 8–11]. This evidence concerns the gene MAPT and Alzheimer disease.